We’re thrilled to share that we're expanding our licensing agreement with @Quanterix to advance next generation Alzheimer's disease biomarker research.
🔗Read the full announcement: alzpath.bio/alzpath-and-quan…
#pTau217 #Quanterix
This #WorldAlzheimersMonth, progress in blood based Alzheimer’s testing offers even more reason for hope.
Years of research are moving closer to clinical practice, with the potential to support more accessible assessment and clearer answers for clinicians, patients & families.
Last week, @Roche received FDA clearance for the Elecsys® pTau217 blood test, developed using ALZpath’s proprietary #pTau217 antibody—an important step toward broader access to blood-based Alzheimer’s disease testing and care.
🔗Read the full release: diagnostics.roche.com/us/en/…
Big news from our partners at @BeckmanDx: Beckman Coulter announced CE Mark for its Access p-Tau217 assay, developed using ALZpath’s proprietary pTau217 antibody.
🔗Read the full announcement: prnewswire.com/news-releases…
Just 1 week until #AAIC26.
ALZpath is looking forward to attending AAIC 2026 next week in London.
If you’re attending, we welcome the opportunity to connect. To schedule a time with the ALZpath team, reach out to Jacob Hunter at [email protected].
We'll see you there!
ALZpath Signs Global Licensing Agreement with @AbbottNews to Advance Blood-Based Alzheimer's Disease Testing
The agreement will incorporate ALZpath’s proprietary pTau217 antibody into development of an IVD test for use on Abbott’s Alinity ci-series systems.
We’re attending AAIC 2026! 🧠
Join ALZpath in London, July 12-15th.
Attending AAIC 2026 and interested in connecting? Reach out to Jacob Hunter at [email protected] to schedule a meeting with our team.
We'll see you there!
🧠 June is Alzheimer's & Brain Awareness Month.
This month, we recognize the individuals, families, caregivers and communities impacted by Alzheimer's disease, along with those dedicated to advancing awareness, research, diagnosis, and care.
#AlzheimersDisease #ENDALZ
With @adpdnet 2026 underway in Copenhagen, research featuring ALZpath’s pTau217 antibody appears across 29 scientific presentations.
Highlights from this week’s program below.
🔗 Read more: alzpath.bio/broad-ad-pd-2026…
1 week until AD/PD™ 2026 🧠
The global Alzheimer’s disease and Parkinson’s disease community will gather in Copenhagen, March 17–21.
Attending and want to connect? Reach out to Jacob Hunter at [email protected] to schedule a meeting.
